Cao A et al., 2019-03: Systematic review of 19 randomised trials (1,635 patients) of astragalus injection with platinum chemotherapy in advanced NSCLC, reporting a halving of leukopenia risk alongside better response, but rated low quality by GRADE and described by its authors as a weak recommendation.
The results showed that the level of evidence was low. CONCLUSIONS: The AGI apparently has attenuation and synergistic efficacy to platinum-based chemotherapy patients. However, considering the limits of articles included in the present researches, the recommendation is likely to be weak. High-quality RCTs are urgently used to generate conclusive results.
Abstract, Results and Conclusions
Cao A et al., 2019-03: Systematic review of 19 randomised trials (1,635 patients) of astragalus injection with platinum chemotherapy in advanced NSCLC, reporting a halving of leukopenia risk alongside better response, but rated low quality by GRADE and described by its authors as a weak recommendation. Bears directly on the book's white-blood-cell claim: leukopenia RR 0.52 (95% CI 0.44-0.61) comes with 'the level of evidence was low'. All trials Chinese; authors declare no conflicts; funder not stated. Comparator: platinum chemotherapy alone. Study type: review.
